Dermatomyositis Market Size is Set for Rapid Growth as Innovative Treatments and Rising Awareness Drive Demand by 2032

The Dermatomyositis market size is expected to increase during the forecast period with the increasing prevalence, disease awareness, and promising emerging treatment options by leading companies such as Priovant Therapeutics, Pfizer, AstraZeneca, Argenx, CSL Behring, Janssen (Johnson & Johnson), Merck, Horizon Therapeutics, Kezar Life Sciences, Onyx therapeutics, Immunoforge, Galapagos NV, Adienne Pharma & Biotech

[Nevada, United States] - DelveInsight's "Dermatomyositis Market Insights, Epidemiology, and Market Forecast 2032." report offers a detailed examination of Dermatomyositis, covering historical and predicted epidemiology, market trends, and treatment scenarios in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.

To Know in detail about the Dermatomyositis Market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Key Findings from the Dermatomyositis Market Report:
• The Dermatomyositis market size is poised for significant growth, with an anticipated Compound Annual Growth Rate (CAGR) during the study period (2019-2032).
• In October, 2024: AstraZeneca announced a Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared With Placebo Added to Standard of Care in Adult Participants With Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)
• In October, 2024: Amgen announced that their Phase 2, Randomized, Double-blind, Placebo-controlled, Efficacy and Safety Study of Daxdilimab Subcutaneous Injection in Adult Participants With Inadequately Controlled Dermatomyositis or Anti-synthetase Inflammatory Myositis.
• In October, 2024: Pfizer announced a phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of pf-06823859 in participants with active idiopathic inflammatory myopathies (including participants with active dermatomyositis or polymyositis)
• In October, 2024: argenx announced a Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older with Active Idiopathic Inflammatory Myopathy
• In September, 2024: CSL Behring announced a Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults With Dermatomyositis (DM) - The RECLAIM Study
• According to DelveInsight's estimate, the total diagnosed prevalent cases of dermatomyositis in the 7MM were approximately 71 thousand in 2023. These cases are expected to increase during the forecast period (2024-2034).
• As per the estimates, among the severity-specific diagnosed prevalent cases of dermatomyositis, there were approximately 21 thousand mild and 17 thousand moderate to severe cases of dermatomyositis in the US in 2023.
• vAmong the age-specific diagnosed prevalent cases of dermatomyositis, the highest number of cases were found in the 40─59 and 60─79 age group accounting for approximately 25 thousand cases in each age group in the 7MM in 2023.
• Key Dermatomyositis Companies are as follows: Priovant Therapeutics, Pfizer, AstraZeneca, Argenx, CSL Behring, Janssen (Johnson & Johnson), Merck, Horizon Therapeutics, Kezar Life Sciences, Onyx therapeutics, Immunoforge, Galapagos NV, Adienne Pharma & Biotech
• Key Dermatomyositis Therapies are as follow: OCTAGAM 10% (immunoglobulin), Brepocitinib (PF-06700841), ULTOMIRIS (ravulizumab/ALXN1210), Efgartigimod, PF-06823859 (anti-beta interferon), GLPG3667, Anifrolumab (blinded), Daxdilimab, immunoglobulin, KZR-616, Brepocitinib
• Launching multiple stage Dermatomyositis pipeline products is expected to revolutionize market dynamics, further propelling market growth.

Dive into our detailed Dermatomyositis market research report to uncover actionable insights, industry forecasts, and competitive analysis @ https://www.delveinsight.com/report-store/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dermatomyositis Overview:
Dermatomyositis is a complex and heterogeneous condition that occurs in both adults and even in children, juvenile dermatomyositis (JDM). They share the hallmark features of pathognomic skin rash and muscle inflammation but are heterogeneous disorders with various additional features and complications.

Dermatomyositis Epidemiology Segmentation:
The Dermatomyositis market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Dermatomyositis Total Diagnosed Prevalent Cases
• Dermatomyositis Gender-specific Diagnosed Prevalent Cases
• Dermatomyositis Chronicity-specific Diagnosed Prevalent Cases
• Dermatomyositis Age-specific Diagnosed Prevalent Cases

For more information about Dermatomyositis companies working in the treatment market, visit https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dermatomyositis Market Insights
There is no cure for dermatomyositis; however, medication can reduce inflammation and vasculitis, invariably minimize symptomatology, and improve the patient's quality of life. Several off-label medications, including corticosteroids, immunosuppressants, antimalarial drugs, antibiotics, and topical ointments, are combined to eliminate symptoms.

Dermatomyositis Drugs Uptake
• OCTAGAM 10% (immune globulin intravenous [human]) is the first and only intravenous immunoglobulin (IVIg) product indicated for the treatment of primary humoral immunodeficiency, chronic immune thrombocytopenic purpura (ITP) and dermatomyositis.
• Brepocitinib is a potential first-in-class dual inhibitor of tyrosine kinase (TYK2) and Janus kinase 1 (JAK1). Its novel mechanism of action potentially provides greater efficacy in multiple highly inflammatory autoimmune diseases than agents that inhibit either TYK2 or JAK1 alone.
• PF-06823859 is a humanized immunoglobulin G (IgG1K) monoclonal antibody that works as an interferon, beta one fibroblast (IFNβ1) blocker and is under development to treat patients suffering from dermatomyositis, and polymyositis.
• PF1801 (froniglutide), a recombinant glucagon-like peptide-1(GLP 1) analog elastin-like peptide (ELP)-120 fusion protein that acts on glucagon-like peptide 1 receptor (GLP-1R) and has pleiotropic actions including anti-inflammatory effects, prevention of muscle atrophy, muscle inflammation in C protein‐induced myositis and dermatomyositis patients.

Dive into our comprehensive market research report to discover in-depth insights, emerging trends, and strategic opportunities @ https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dermatomyositis Therapies and Key Companies:
• OCTAGAM 10% (immunoglobulin): Octapharma
• Brepocitinib (PF-06700841): Priovant Therapeutics/Pfizer
• ULTOMIRIS (ravulizumab/ALXN1210): AstraZeneca
• Efgartigimod: Argenx
• PF-06823859 (anti-beta interferon): Pfizer
• GLPG3667: Galapagos NV
• Anifrolumab (blinded): AstraZeneca
• Daxdilimab: Amgen
• immunoglobulin: CSL Behring
• KZR-616: Kezar Life Sciences, Inc.
• Brepocitinib: Priovant Therapeutics, Inc.

Dermatomyositis Epidemiology:
In 2023, the US accounted for approximately 26 thousand female and 12 thousand male cases of dermatomyositis. In EU4 and the UK, Germany had the highest diagnosed prevalent cases of dermatomyositis, of which around 67% were females and 33% were males. In the UK, among the comorbidities-specific cases, other diseases (osteoporosis, dysphagia, Raynaud's syndrome, calcinosis, etc.), cancer malignancy, cardiovascular disease, and intestinal lung disease accounted for nearly 18 hundred, 13 hundred, 4 hundred and 9 hundred cases, respectively, in 2023.

Seize Market Opportunities with Our Expert Analysis! Our report delivers valuable insights into market dynamics, key players, and emerging trends @ https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Dermatomyositis Market Drivers:
• A significant increase in knowledge and understanding of disease pathogenesis has led to the identification of various novel MoAs targeting C5 complement, IFNβ1, FcRn, and others.
• Established diagnostic and clinical guidelines for adult and juvenile dermatomyositis enable informed treatment and management of patients.
• Better prognostic markers would allow physicians to diagnose and begin treatment at early onset, possibly preventing disease progression.

Dermatomyositis Market Barriers:
• Therapeutic options for dermatomyositis center around off-label medication, including corticosteroids, which are associated with several side effects and adverse events like osteoporosis, increased susceptibility to infections, cushingoid features, and others.
• Dermatomyositis is rare and remains relatively unknown compared to other myopathies, resulting in lower awareness among healthcare professionals and the general public.
• Dermatomyositis is associated with serious complications and comorbidities, such as interstitial lung disease, cardiovascular disease, or malignancies.

Stay Ahead in a Competitive Landscape with Our Exhaustive Market Research Report-Dive Into Detailed Analysis, Key Trends, and Future Projections @ https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Scope of the Dermatomyositis Market Report:
• Study Period: 2019-2032
• Coverage: 7MM (The United States, EU5, and Japan)
• Key Dermatomyositis Companies: Priovant Therapeutics, Pfizer, AstraZeneca, Argenx, CSL Behring, Janssen (Johnson & Johnson), Merck, Horizon Therapeutics, Kezar Life Sciences, Onyx therapeutics, Immunoforge, Galapagos NV, Adienne Pharma & Biotech
• Key Dermatomyositis Therapies: OCTAGAM 10% (immunoglobulin), Brepocitinib (PF-06700841), ULTOMIRIS (ravulizumab/ALXN1210), Efgartigimod, PF-06823859 (anti-beta interferon), GLPG3667, Anifrolumab (blinded), Daxdilimab, immunoglobulin, KZR-616, Brepocitinib
• Dermatomyositis Therapeutic Assessment: Current marketed and emerging therapies
• Dermatomyositis Market Dynamics: Dermatomyositis Market drivers and Dermatomyositis barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Dermatomyositis Unmet Needs: Insights into unmet needs, KOL's views, Analyst's views, Market Access, and Reimbursement.

To access the full report and gain a deeper understanding of Dermatomyositis market outlook, drug uptake, treatment scenario, and epidemiology trends, https://www.delveinsight.com/sample-request/dermatomyositis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rkpr

Table of Content:

1. Key Insights
2. Report Introduction
3. Dermatomyositis Market Overview at a Glance
4. Methodology of Dermatomyositis Epidemiology and Market
5. Executive Summary of Dermatomyositis
6. Key Events
7. Disease Background and Overview
8. Patient Journey
9. Epidemiology and Patient Population
10. Marketed Drugs
11. Emerging Drugs
12. Dermatomyositis: Market Analysis
13. Key Opinion Leaders' Views
14. SWOT Analysis
15. Unmet Needs
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About Delveinsight

About DelveInsight:
DelveInsight is a leading market research firm providing insightful solutions and services to pharmaceutical and life sciences companies. With a commitment to delivering accurate and comprehensive reports, DelveInsight empowers businesses to make informed decisions and navigate the complexities of the healthcare industry.

Contact Information:
Company Name: DelveInsight Business Research LLP
Contact Person: Ram Kapoor
Email: info@delveinsight.com
Contact No.: +91-9650213330
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

This release was published on openPR.